As shown on figure 4D, stimulation of MCL cells with CD40L+IL4 did not prevent the decrease in cell proliferation either in acadesine, rituximab-, or the combination, contrasting with what observed when MCL cells were incubated with bortezomib. Here, IL4 is linked to mantle cell lymphoma.